Needham Maintains Buy on Evommune, Lowers Price Target to $25
Needham analyst Serge Belanger maintains Evommune (NYSE:EVMN) with a Buy and lowers the price target from $28 to $25.
Last updated: 2026-11-13 23:30:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Evommune, Inc. (EVMN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $7.64, with a market capitalization of $291.06M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.94 to $33.20. This page covers its latest market performance, valuation, price trends and company information.
$291.06M | |
$8.18 | |
$8.18 | |
$7.43 | |
$8.02 | |
694.00K | |
825.43K | |
-- | |
$33.20 | |
$4.94 | |
-- | |
-- |
Evommune, Inc. (EVMN) is trading at $7.65 in after-hours trading as of 2026-11-13 21:20:00, up 0.09% ($0.01) from the regular-session close of $7.64.
After-hours trading shows how investors are pricing EVMN after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Evommune, Inc. (EVMN) moved from $6.04 to $7.64, representing a gain of 26.46% ($1.60).
The stock traded between $5.82 and $8.93 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 867.85 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 9.5%
EVMN is currently trading at $7.64, placing it 9.5% of the way from its 52-week low of $4.94 to its 52-week high of $33.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 48 |
| Exchange | NYSE |
| Company Website |
Latest news related to Evommune, Inc. and EVMN stock.
Needham analyst Serge Belanger maintains Evommune (NYSE:EVMN) with a Buy and lowers the price target from $28 to $25.
Evommune (NYSE:EVMN) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.84) by 1.19 percent. This is a 89.47 percent increase over losses of $(8.07) per share from the same
Pelthos Therapeutics reported a Q3 loss of $3.09 per share, missing consensus estimates of $2.83 loss, and posted revenues of $15.4 million, falling 15.34% short of expectations. Despite the miss, the company showed improvement from a year-ago loss of $5.3 per share. The stock has declined 69.7% year-to-date while the S&P 500 gained 11.3%. Zacks assigned the stock a Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.
Eligible investors can buy real shares of Evommune, Inc. (EVMN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to EVMN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between EVMN shares and USD.
EVMN Shares to USD
1.00 EVMN shares = 7.638 USD
Calculations are estimates based on the latest available price and are for reference only.